(E)-5-(2-Bromovinyl)-2'-deoxyuridine is a potent antiherpes compound with far better activity against herpes simplex virus type 1 than type 2. To understand the role of drug metabolism in this differential antiviral activity, we examined the metabolic fate of this drug in virus-infected and mock-infected Vero cells by high-pressure liquid chromatography. After 8 h of incubation in which cells were exposed to 10 ,ig of (E)-5-(2-Bromovinyl)-2'-deoxyuridine (BVdU) is an antiherpes compound with comparatively high potency in cell culture and efficacy in a variety of animal models (4, 5) . It has demonstrated type specificity for herpes simplex virus type 1 (HSV-1), with a reduction of antiviral potency of 50 to 500 times against HSV-2 (5, 10).
(E)-5-(2-Bromovinyl)-2'-deoxyuridine (BVdU) is an antiherpes compound with comparatively high potency in cell culture and efficacy in a variety of animal models (4, 5) . It has demonstrated type specificity for herpes simplex virus type 1 (HSV-1), with a reduction of antiviral potency of 50 to 500 times against HSV-2 (5, 10).
Phosphorylation by the viral thymidine kinase has been suggested to be responsible, at least in part, for the antiviral activity of this compound (3) . BVdU has a markedly higher affinity for the HSV-1-induced thymidine kinase than the HSV-2-induced thymidine kinase (3) , although in vitro monophosphorylation by the HSV-2-specified enzyme is slightly faster than mnonophosphorylation by the HSV-1-specified enzyme (3, 9) . The HSV-1-specified thymidylate kinase activity is able to further phosphorylate BVdU monophosphate (BVdUMP) in vitro to BVdU diphosphate (BVdUDP). The HSV-2-specified kinase has only 2% of the activity of the parallel HSV-1 enzyme when thymidine monophosphate is used as the substrate. Furthermore, the HSV-2-specified thymidylate kinase cannot use BVdUMP as a substrate in vitro (9) . These The samples were then centrifuged at 2,000 x g at 4°C for 10 min. The supernatant was then removed and mixed with 0.2 ml of IVdU (150 pg per ml) to measure recovery. This extract was neutralized with a mixture of 2 M KOH and 0.5 M K2HPO4 and centrifuged at 2,000 x g at 4°C for 10 min, and the supernatant was freeze-dried. The freeze-dried samples were redissolved in glass-distilled water (0.3 or 0.4 ml) and assayed by HPLC. To ascertain whether BVdUTP, BVdUDP, and BVdUMP are broken down during acid extraction, the compounds were separately added to mockinfected and HSV-infected cell samples and extracted.
HPLC analyses of cell extracts. HPLC methods were modified from those of Hoffman and Liao (10) . The concentration of BVdU was calibrated with IVdU as an internal standard. The temperature of the HPLC oven was 48°C, and the detector was set at 292 nm, 0.04 absorbance units, full scale. A linear gradient in methanol (25 to 50% [vol/vol] in water) was used with solvents containing 0.0125 M tetrabutylammonium bromide and 0.05 M NaH2PO4 (the pH was adjusted to S by the addition of NaOH). Each sample (10 RI) was injected, and the flow rate was 1 ml/min. The lowest level of quantitative detection (two times the signal-to-noise ratio) was 1.6 ,uM for all compounds. Identification of the compounds was based on their retention times, which under these conditions were (in minutes): BVU, 4.8; BVdU, 5.5; BVdUMP, 6.7; IVdU, 7.7; BVdUDP, 11.9; and BVdUTP, 13.9. In addition, all compounds were identified as BVdU derivatives by their unique ratios of absorbance (absorbancy at 292 nm/absorbancy at 254 nm).
RESULTS
The results of one HPLC analysis of extracts of mock-infected Vero cells are shown in Fig. 1A . The IVdU internal standard was demonstrated, and a small but recordable additional peak was present at 5.5 min, representing BVdU. Results from HSV-1-infected cells are shown in Fig. 1B . In this example of virus-infected cells (McIntyre), BVdU uptake was increased compared with that in mock-infected cells. Furthermore, peaks of BVdUMP, BVdUDP, and BVdUTP also were seen. HSV-2-infected cells showed peaks of BVdU and BVdUMP, but further phosphorylation beyond BVdUMP did not take place in these cells (Fig. 1C) .
The absolute values of the concentrations of BVdU and its nucleotides, as found in a series of experiments with different virus strains, are presented in Table 1 good substrate for HSV-specified thymidine kinase (EC 2.7.1.75) with a Ki of 0.24 ,uM for the HSV-1-specified enzyme and 4.24 ,uM for the HSV-2-specified enzyme, although phosphorylation rates are better with HSV-2 extracts (3, 9). BVdUMP also serves as a substrate for HSV-1-specified thymidylate kinase (9) . This enzyme catalyzes the phosphorylation of thymidylate to its diphosphate and is present in quantities of 50:1 for HSV-1 versus HSV-2. HSV-1-infected cell extracts catalyze the conversion of BVdUMP to BVdUDP in vitro, whereas HSV-2-infected cell extracts do not. Presumably, after further phosphorylation, BVdUTP exerts its antiviral effects via inhibition of DNA polymerase (1, 15) . This step, however, is not type specific (15) . BVdUTP can also be incorporated into viral DNA, thereby causing single-strand breaks (13) . It is therefore possible that small amounts of BVdUDP may be formed in HSV-2-infected cells and are incorporated into viral DNA, resulting in no detectable amounts of this metabolite by our method. Thus, the final antiviral action of BVdUTP may reside in the production of fraudulent DNA. Type specificity, however, is determined by conversion of BVdUMP to the diphosphate and subsequently to the triphosphate; this conversion would appear to occur exclusively in HSV-1-infected cells. The fact that no breakdown of BVdUTP, BVdUDP, and BVdUMP occurred during acid extraction demonstrates that the variable amounts of BVdU derivatives detected in our experiments were not due to chemical or enzymatic, or both, breakdown of these compounds.
Previous observations made by Descamps and De Clercq (6) with silica gel thin-layer chromatography are also of interest. In this previous experiment, 125-labeled IVdU was used as a probe. IVdU compound is another 5-substituted 2'-deoxyuridine which also shows HSV-1 specificity (5). 125-labeled IVdU is phosphorylated to the monophosphate in both HSV-1-and HSV-2-infected cells with two additional unidentified compounds detected in HSV-1-infected cells (6) . By using a different cell line, relatively large quantities of parent compound were incorporated into mock-infected cells. These differences might be attributed to the high specific activity of their radiolabel, as well as differences in cell type and agent tested. Uptake of BVdU into cells was enhanced by HSV infection in our study, although this may be a nonspecific permeability effect, since similar differences in nucleoside analog uptake are seen with acyclovir in infected cells (8) . Uptake of BVdU was virus strain dependent and for one strain (McIntyre) was also inoculum dependent. BVdU incorporation also correlated to the amount of total phosphorylation, suggesting that drug anabolism is partly responsible for facilitated transport in HSV-infected cells.
Small amounts of BVU were detected in cells infected with HSV-2 strains G and 150. It is not known whether HSV can hydrolyze BVdU on the basis of an HSV-induced enzyme, although several mammalian nucleoside phosphorylases will use BVdU as a substrate (12) . BVU also has been detected in the plasma of rats given BVdU by the intraperitoneal route (7) and in the plasma of immunosuppressed patients treated orally with BVdU (R. J. Whitely, N. H. Barton, J. Welchel, A. G. Diethelm, J. Curtis, R. Luke, and A. S. Kulkarni, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 23rd, Las Vegas, Nev., abstr. no. 145, 1983 ). Further work is needed to elucidate the mechanism of BVU production in HSV-infected cells and its biological significance.
We have shown that the greater activity of BVdU against HSV-1 as compared with HSV-2 parallels the ability of virus-infected cells to produce BVdUDP and BVdUTP in situ. In addition, we have recently analyzed the 50% infective doses of BVdU in Vero cells with the HSV-1 isolates described in this paper, and they are 0.02, 0.04, and 0.06 ,ug/ml for McIntyre, 413, and F, respectively (data not shown). This would suggest a possible correlation with antiviral effect even within various HSV-1 strains.
HPCL offers a sensitive probe for monitoring the metabolism of antiviral compounds in the cell which may permit a more detailed examination of the mechanisms of action of the nucleoside analogs as they occur in situ. Further work should concentrate on both defining the kii.etics of this system as altered by environmental changes, drug concentrations, virus inoculum, cell type, and drug antidotes and correlating the observed metabolic results with the in vitro antiviral effects. Further work might also be directed at establishing the consequences of metabolic trapping of BVdU at the monophosphate level in HSV-2-infected cells where it might serve as an alternative substrate for thymidylate synthetase (EC 2.1.1.45) and thus be converted to a series of metabolites which have decreased antiviral properties, as previously observed (2) .
